Lung cancers with ALK rearrangement represent less than 5% of all lung cancers. ALK inhibitors are currently used to treat first-line metastatic non-small cell lung cancer with ALK rearrangement. Compared to chemotherapy, ALK inhibitors have improved progression-free survival, overall survival, and quality of life for patients. The results of several phase 3 studies with a follow-up of over 6 years suggest that the life expectancy of these patients treated with targeted therapies is significantly higher than 5 years and could approach 10 years. Nevertheless, these treatments induce haematological toxicities, including neutropenia. Few data are available on neutropenia induced by ALK inhibitors and on the pathophysiological mechanism and therapeutic adaptations necessary to continue the treatment. Given the high efficacy of these treatments, managing side effects to avoid treatment interruptions is essential. Here, we have reviewed the data from published clinical studies and case reports to provide an overview of neutropenia induced by ALK inhibitors.
ALK重排肺癌在所有肺癌中占比不足5%。目前ALK抑制剂被用于治疗一线转移性ALK重排非小细胞肺癌。与化疗相比，ALK抑制剂显著改善了患者的无进展生存期、总生存期及生活质量。多项随访超过6年的三期临床研究结果表明，接受靶向治疗的此类患者预期寿命显著超过5年，甚至可能接近10年。然而，这类治疗会引发血液学毒性反应，包括中性粒细胞减少症。目前关于ALK抑制剂所致中性粒细胞减少症的病理生理机制及维持治疗所需调整方案的数据较为有限。鉴于此类疗法的高效性，有效管理副作用以避免治疗中断至关重要。本文通过综述已发表的临床研究及病例报告数据，系统阐述ALK抑制剂引发中性粒细胞减少症的研究现状。
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
肿瘤(癌症)患者之家